刘俊彦博士，2020年3月起任重庆医科大学生命科学研究院特聘教授（拔尖人才岗），博士研究生导师。2003年6月获南京大学理学博士学位，随后在南京大学从事博士后研究， 05年获副研究员资格。2005年5月至2012年9月在美国加州大学戴维斯分校（UCD）工作，历任博士后 (05/05-09/05)，助理研究员（09/06-12/09），和NIEHS-UCD超级研究计划分析中心常务副主任（11/03-12/09）。2012年10月至2014年4月任美国麦润生物科技创新公司资深研究员。2015年5月起全职回国任同济大学附属第十人民医院教授，同济大学医学院肾脏病代谢组学研究中心常务副主任。主要从事代谢组学与生命分析化学、药理学与天然药物化学等方面的研究。是中国药理学会肾脏药理专委会全国委员，美国药理和实验治疗协会（ASPET）会员。是国家自然科学基金委通讯评议人，教育部科技评价与评审系统专家，还是 Chem Eng J、Cancer Immunol Res、Signal Transduct Target Ther、Trends Analyt Chem、Kidney Int、Theranostics、Br J Pharmacol等十余种SCI杂志审稿人。曾获中国博士后基金, 江苏省博士后基金，上海市科委自然科学基金，和国家自然科学基金面上项目资助。已在Proc Natl Acad Sci USA、Cancer Res、Mol Cancer Ther、Br J Pharmacol、Biochem Pharmacol等杂志发表论文60余篇，Google Scholar引用3700余次，h-index 32。曾获中国教育部自然科学一等奖一项，NIEHS-UCD超级研究计划配套基金奖，ASPET学术年会旅行奖等。

代表性论文：

1. Wang Z#, Li Z-X#, Zhao WC, Huang HB, Wang JQ, Zhang H, Lu JY, Wang RN, Li W, Cheng Z, Xu WL, Zhu D, Zhou LS, Jiang W, Yu L, Liu JY, Luo C, Zhu H, Ye D, Pan WJ, Ju JH, Dang YJ*. (2021) Identification and characterization of isocitrate dehydrogenase 1 (IDH1) as a functional target of marine natural product grincamycin B. (DOI: 10.1038/s41401-020-0491-6, Epub ahead of print, 08/14/2020)

2. Singh N#, Barnych B#, Morisseau C, Wagner K, Wan D, Takeshita A， Pham H， Xu T， Dandekar A， Liu JY and Hammock BD*. (2020) N-benzyl-linoleamide, a constituent of lepidium meyenii (maca), is an orally bioavailable soluble epoxide hydrolase inhibitor that alleviates inflammatory pain. Journal of Natural Products 83: 3689-3697 (https://doi.org/10.1021/acs.jnatprod.0c00938)

3. Song YX#, Fan SL#, Peng A, Shen SJ, Liu XY, Li CB, Hu DY, Xue W, Li XH, Jiang CZ, Li XH*, Liu JY*. (2020) A retrospective analysis reveals a predictor of survival for the patient with paraquat intoxication. Clinica Chimica Acta 511: 269-277 (https://doi.org/10.1016/j.cca.2020.10.027)

4. Luo Y and Liu JY*. (2020) Pleiotropic functions of cytochrome P450 monooxygenase-derived eicosanoids in cancer. Frontiers in Pharmacology. 11: 580897 （doi: 10.3389/fphar.2020.580897）

5. Guo LP, Wang Q, Pan Y, Wang YL, Zhang ZJ, Hu C, Ding F, Peng A*, #, Liu JY#. (2020) A retrospective cross-sectional study of the associated factors of hyperuricemia in patients with chronic kidney disease. The Journal of International Medical Research 48 (6): 1-13 (https://doi.org/10.1177/0300060520919224, First Published: 06/12/2020)

6. Shen Y#, Peng W#, Chen Q, Hammock BD, Liu JY, Li D, Yang J, Ding J*, Wang X*. (2019) Anti-inflammatory treatment with a soluble epoxide hydrolase inhibitor attenuates seizures and epilepsy-associated depression in the LiCl-pilocarpine post-status epilepticus rat model. Brain Behavior and Immunity 81:535-544 (doi: 10.1016/j.bbi.2019.07.014 Epub ahead of print, 07/12/2019)

7. Wang W#, Yang J#, Edin ML#, Wang YX#, Luo Y, Wan DB, Shih PB, Yang HX, Song CQ, Xue W, Sanidad KZ, Song MY, Bisbee HA, Bradbury JA, Nan GJ, Zhang JN, Minter LM, Kim D, Xiao H, Liu JY, Hammock BD*, Zeldin DA*, Zhang G*. （2019）Targeted metabolomics identifies the cytochrome P450 monooxygenase eicosanoid pathway as a novel therapeutic target of colon tumorigenesis. Cancer Research 79 (8): 1822-1830 (doi: 10.1158/0008-5472.CAN-18-3221, Epub ahead of print, 02/25/2019)

8. Luo Y, Wu MY, Deng BQ, Huang J, Hwang SH, Li MY, Zhou CY, Zhang QY, Yu HB, Zhao DK, Qin L, Peng A, Zhang G, Hammock BD*, Liu JY*. (2019) Inhibition of soluble epoxide hydrolase attenuates a high fat diet-mediated renal injury by activating PAX2 and AMPK. Proceedings of the National Academy of Sciences of the United States of America. 116(11):5154-5159 (DOI: 10.1073/pnas.1815746116, Epub ahead of print, 02/25/2019)

9. Luo Y, Wang L, Peng A and Liu JY*. (2019) Metabolic profiling of human plasma reveals the activation of 5-lipoxygenase in the acute attack of gouty arthritis. Rheumatology 58： 345-351 (doi:10.1093/rheumatology/key284, Epub ahead of print 09/20/2018)

10. Liu JY*. (2019) Inhibition of soluble epoxide hydrolase for renal health. Frontiers in Pharmacology. (Invited review) 9：1551 (DOI: 10.3389/fphar.2018.01551， Epub ahead of print，01/10/2019)

11. Hu DY#, Luo Y#, Li, CB, Zhou CY, Li XH, Peng A, Liu JY*. (2018) Oxylipin profiling of human plasma reflects the renal dysfunction for uremic patients. Metabolomics 14: 104 (DOI: 10.1007/s11306-018-1402-4, Epub ahead of print 08/01/ 2018)

12. Luo Y, Wang L, Liu XY, Chen X, Song YX, Li XH, Jiang C, Peng A* and Liu JY*. (2018) Plasma profiling of amino acids distinguishes acute gout from asymptomatic hyperuricemia. Amino acids 50 (11): 1539-1548 (DOI: 10.1007/s00726-018-2627-2, Epub ahead of print 08/02/ 2018)

13. Wang W#, Yang J#, Zhang J#, Wang Y, Hwang SH，Qi W, Wan D, Kim D, Sun J, Sanidad KZ, Yang H, Park Y, Liu JY, Zhao X, Zheng X, Liu Z, Hammock BD*, Zhang G*. (2018）Lipidomic profiling reveals soluble epoxide hydrolase as a therapeutic target of obesity-induced colonic inflammation. Proceedings of the National Academy of Sciences of the United States of America. 115(20): 5283-5288 (DOI: 10.1073/pnas.1721711115. Epub 05/01/2018)

14. Liu XY#, Luo Y#, Zhou CY, Peng A, Liu JY*. (2017) A sensitive and accurate method to simultaneously measure uric acid and creatinine in human saliva by using LC-MS/MS. Bioanalysis 9：1751-1760 (DOI: 10.4155/bio-2017-0189, Epub ahead of print, 10/02/2017)

15. Deng BQ, Luo Y, Kang X, Li CB, Morisseau C, Yang J, Lee KSS, Huang J, Hu DY, Wu MY, Peng A, Hammock BD*, Liu JY*. (2017) Epoxide metabolites of arachidonate and docosahexaenoate function conversely in acute kidney injury involved in GSK3β signaling. Proceedings of the National Academy of Sciences of the United States of America 114 (47): 12608-12613 (DOI: www.pnas.org/cgi/doi/10.1073/pnas.1705615114, Epub ahead of Print, 11/06/2017)

16. Liu JY*, Morisseau C, Huang H, Hammock BD. (2016) Screening of soluble epoxide hydrolase inhibitory ingredients from traditional Chinese medicines for anti-inflammatory use. Journal of Ethnopharmacology 194: 475-482 (DOI: 10.1016/j.jep.2016.09.044)

17. Liao J, Hwang SH, Li H, Yang Y, Yang J, Wecksler AT, Liu JY, Hammock BD and Yang GY*. (2016) Inhibition of mutant Kras-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM. Cancer Letters 371(2): 187-193 (DOI: 10.1016/j.canlet.2015.11.042)

18. Cao LL, Zhang YY, Liu YJ, Yang TT, Zhang JL, Zhang ZG, Shen Li, Liu JY, Ye YH*. (2016) Anti-phytopathogenic activity of sporothriolide, a metabolite from endophyte Nodulisporium sp. A21 in Ginkgo biloba. Pesticide Biochemistry and Physiology 129: 7-13 (DOI: 10.1016/j.pestbp.2015.10.002)

19. Zhou R#, Kang X#, Tang B#, Mohan C, Wu T, Peng A* and Liu JY*. (2016) Ornithine is a key mediator in hyperphosphatemia-mediated human umbilical vein endothelial cell apoptosis: insights gained from metabolomics. Life Sciences 146: 73-80 (DOI: 10.1016/j.lfs.2016.01.003)

20. Liao J, Hwang SH, Li H, Liu JY, Hammock BD, Yang GY*. (2016) Inhibition of chronic pancreatitis and murine pancreatic intraepithelial neoplasia by a dual inhibitor of c-RAF and soluble epoxide hydrolase in LSL-KrasG12D/Pdx-1-Cre mice. Anticancer Research 36(1): 27-37 (WOS:000367450000005)

21. Liu JY#, Tsai HJ#, Morisseau C, Lango J, Hwang SH, Watanabe T, Kim IH, and Hammock BD*. (2015) In vitro and in vivo metabolism of N-adamantyl substituted urea-based soluble epoxide hydrolase inhibitors. Biochemical Pharmacology 98(4):718-731 (DOI: 10.1016/j.bcp.2015.10.013)

22. Kang X, Hu DY, Li CB, Li LH, Fan SL, Liu Y, Tang GY, Ai ZS, Wu TF, Mohan C, Zhou XJ, Liu JY and Peng A*. (2015) Ground Glass Opacity in Early Lung CT predicts mortality in Acute Paraquat Poisoning. Plos ONE 10(4) ：e0121691. (doi:10.1371/journal.pone.0121691)

23. Wecksler A, Hwang SH, Liu JY, Wettersten H, Morrisseau C, Wu J, Weiss R and Hammock BD*. (2015) Biological Evaluation of a Novel Sorafenib Analogue, t-CUPM. Cancer Chemotherapy and Pharmacology 75(1): 161-171 (DOI: 10.1007/s00280-014-2626-2)

24. Yang J, Bratt J, Franzi L, Liu JY, Zhang GD, Zeki AA, Vogel CFA, Williams K, Dong H, Lin YP, Hwang SH, Kenyon NJ and Hammock BD*. (2015) Soluble Epoxide Hydrolase Inhibitor Attenuates Inflammation and Airway Hyperresponsiveness in Mice. American Journal of Respiratory Cell and Molecular Biology 52(1): 46-55 doi: 10.1165/rcmb.2013-0440OC

25. Zhang M, Dai ZC, Qian SS, Liu JY, Xiao Y, Lu AM, Zhu HL, Wang JX, Ye YH*. (2014) Design, synthesis, antifungal and antioxidant activities of (E)-6-((2-phenylhydrazono)methyl)quinoxaline derivatives. Journal of Agricultural and Food Chemistry 62(40), 9637-43 DOI: 10.1021/jf504359p

26. Lee KSS, Liu JY, Wagner KM, Pakhomova S, Dong H, Morisseau C, Fu SH, Yang J, Wang P, Ulu A, Mate CA, Nguyen LV, Hwang SH, Edin ML, Mara AA, Wulff H, Newcomer ME, Zeldin DC and Hammock BD*. (2014) Optimized Inhibitors of Soluble Epoxide Hydrolase Improve in Vitro Target Residence Time and in Vivo Efficacy. Journal of Medicinal Chemistry 57(16) ：7016-30 DOI: dx.doi.org/10.1021/jm500694p

27. Zhang GD, Panigrahy D, Hwang SH, Yang J, Mahakian LM, Wettersten HI, Liu JY, Wang YR, Ingham ES, Tam S, Kieran MW, Weiss RH, Ferrara KW and Hammock BD*. (2014) Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis. Proceedings of the National Academy of Sciences of the United States of America 111 (30)：11127-32 DOI: 10.1073/pnas.1410432111

28. Van Bogaert I, Zhang GD, Yang J, Liu JY, Ye YH, Soetaert W and Hammock BD*. (2013) A method to prepare 20-HETE using multifunctional enzyme type 2 (MFE-2)-negative Starmerella bombicola. Journal of Lipid Research 54 (11): 3215-3219 DOI: 10.1194/jlr.D042226

29. Ulu A, Harris TR, Morisseau C, Miyabe C, Inoue H, Schuster G, Dong H, Liu JY, Weiss RH, Chiamvimonvat N, Imig JD and Hammock BD*. (2013) Anti-inflammatory effects of omega-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II dependent hypertension. Journal of Cardiovascular Pharmacology 62 (3): 285-297 DOI: 10.1097/FJC.0b013e318298e460

30. Ye YH*, Xiao Y, Li HX, Wang MH, Tang HW and Liu JY*. (2013) Flavipin in Chaetomium globosum CDW7, an endophytic fungus from Ginkgo biloba, contributes to antioxidant activity. Applied Microbiology and Biotechnology 97: 7131-7139 DOI: 10.1007/s00253-013-5013-8

31. Zhang GD, Panigrahy D, Mahakian L, Yang J, Liu JY, Lee KSS, Wettersten H, Ulu A, Hu XW, Tam S, Hwang SH, Ingham E, Weiss RH, Ferrara KW and Hammock BD*. (2013) Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth and metastasis. Proceedings of the National Academy of Sciences of the United States of America 110 (16): 6530-6535 DOI: www.pnas.org/cgi/doi/10.1073/pnas.1304321110

32. Sirish P, Li N, Liu JY, Lee KSS, Hwang SH, Qiu H, Ma SM, López JE, Hammock BD, and Chiamvimonvat N*.(2013) Unique mechanistic insights into the beneficial effects of soluble epoxide hydrolase inhibitors in the prevention of cardiac fibrosis. Proceedings of the National Academy of Sciences of the United States of America 110 (14): 5618-5623 DOI: www.pnas.org/cgi/doi/10.1073/pnas.1221972110

33. Liu JY, Lin YP, Qiu H, Morisseau C, Rose TE, Hwang SH, Chiamvimonvat, Hammock BD*. (2013) Substituted phenyl groups improve the pharmacokinetic profile and anti-inflammatory effect of urea-based soluble epoxide hydrolase inhibitors in murine models. European Journal of Pharmaceutical Sciences 48(4-5): 619-627 DOI: 10.1016/j.ejps.2012.12.013

34. Huang H, Yao H, Liu JY, Samra AI, Kamita SG, Cornel AJ, Hammock BD*. (2012) Development of pyrethroid-like fluorescent substrates for glutathione S-transferase. Analytical Biochemistry 431(2): 77-83 DOI: http://dx.doi.org/10.1016/j.ab.2012.09.011

35. Kim IH, Nishi K, Kasagami T, Morisseau C, Liu JY, Tsai H-J, Hammock BD*. (2012) Biologically active ester derivatives as potent inhibitors of the soluble epoxide hydrolase. Bioorganic &Medicinal Chemistry Letters 22(18): 5889-5892 DOI: http://dx.doi.org/10.1016/j.bmcl.2012.07.074

36. Qiu H, Liu JY, Wei D, Li N, Yamoah EN, Hammock BD and Chiamvimonvat N*. (2012) Cardiac-generated prostanoids mediate cardiac myocyte apoptosis after myocardial ischemia. Cardiovascular Research 95 (3): 336-345 DOI: 10.1093/cvr/cvs191

37. Kamita SG, Samra AI, Liu JY, Cornel AJ and Hammock BD*. (2011) Juvenile hormone (JH) esterase of the mosquito Culex quinquefasciatus is not a target of the JH analog insecticide methoprene. PLoS ONE 6: e28392 DOI: 10.1371/journal.pone.0028392

38. Liu JY, Qiu H, Morisseau C, Hwang SH, Tsai HJ, Ulu A, Chiamvimonvat N and Hammock BD*. (2011) Inhibition of soluble epoxide hydrolase contributes to the anti-inflammatory effect of antimicrobial triclocarban in a murine model. Toxicology and Applied Pharmacology 255(2): 200-206 DOI: http://dx.doi.org/10.1016/j.taap.2011.06.017

39. Davis BB, Liu JY, Tancredi DJ, Wang L, Simon SI, Hammock BD and Pinkerton KE*. (2011) The anti-inflammatory effects of soluble epoxide hydrolase inhibitors are independent of leukocyte recruitment. Biochemical and Biophysical Research Communications 410: 494-500 DOI: http://dx.doi.org/10.1016/j.bbrc.2011.06.008

40. Hwang SH, Wagner KM, Morisseau C, Liu JY, Dong H, Wecksler AT and Hammock BD*. (2011) Synthesis and Structure-Activity Relationship Studies of 1,5-Diarylpyrazoles Containing Urea moiety as Novel Dual Inhibitors of Cyclooxygenase-2 and Soluble Epoxide Hydrolase. Journal of Medicinal Chemistry 54: 3037-50 DOI: 10.1021/jm2001376

41. Qiu H, Li N, Liu JY, Harris T, Hammock BD and Chiamvimonvat N*. (2011) Soluble epoxide hydrolase inhibitors and heart failure. Cardiovascular Therapeutics 29: 99-111 (Review) DOI: 10.1111/j.1755-5922.2010.00150.x

42. Li N, Liu JY, Qiu H, Harris T, Sirish P, Hammock BD and Chiamvimonvat N*. (2011) Use of metabolomic profiling in the study of arachidonic acid metabolism in cardiovascular disease. Congestive Heart Failure 17:42-46 (Review) DOI: 10.1111/j.1751-7133.2010.00209.x

43. Liu JY, Li N, Yang J, Li N, Qiu H, Ai D, Chiamvimonvat N, Zhu Y and Hammock BD*. (2010) Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events. Proceedings of the National Academy of Sciences of the United States of America 107: 17017-17022 [Reported by JAMA (2010 304:1888) and hundreds of Medias such as EurekAlert, ScienceDaily, Heartwire, Physorg, American Medical Network, ScienceCodex, Los Angeles Times, Molecularstation, e Science News, and etc.] DOI: 10.1073/pnas.1011278107

44. Huang SX, Li HY, Liu JY, Morisseau C, Hammock BD and Long YQ*. (2010) Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties. Journal of Medicinal Chemistry 53: 8376-8386 DOI: 10.1021/jm101087u

45. Rose TE, Morisseau C, Liu JY, Inceoglu B, Jones PD., Sanborn JR, Hammock BD*. (2010) 1-Aryl-3-(1-acylpiperidin-4-yl)urea Inhibitors of Human and Murine Soluble Epoxide Hydrolase: Structure-Activity Relationships, Pharmacokinetics and Reduction of Inflammatory Pain. Journal of Medicinal Chemistry 53: 7067-7075 DOI: 10.1021/jm100691c

46. Liu JY, Yang J, Inceoglu B, Qiu H, Ulu A, Hwang SH, Chiamvimonvat N and Hammock BD*. (2010) Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochemical Pharmacology 79: 880-887 DOI: 10.1016/j.bcp.2009.10.025

47. Li N, Liu JY, Timofeyew V, Qiu H, Hwang SH, Tuteja D, Lu L, Yang J, Mochida H, Low R, Hammock BD and Chiamvimonvat N*. (2009) Beneficial effects of soluble epoxide hydrolase inhibitors in a myocardial infarction model: Insight gained using metabolomic approaches. Journal of Molecular and Cellular Cardiology 47: 835-845 DOI: 10.1016/j.yjmcc.2009.08.017

48. Liu JY, Park SH, Morisseau C, Hwang SH, Hammock BD and Weiss RH*. (2009) Sorafenib has sEH inhibitory activity which contributes to its effect profile in vivo. Molecular Cancer Therapeutics 8: 2193-2203 DOI: 10.1158/1535-7163.MCT-09-0119

49. Liu JY, Tsai HJ, Hwang SH, Jones PD, Morisseau C and Hammock BD*. (2009) Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation. British Journal of Pharmacology 156: 284-296 DOI: 10.1111/j.1476-5381.2008.00009.x

50. Hu SC, Hong K, Song YC, Liu JY and Tan RX*. (2009) Biotransformation of soybean isoflavones by a marine Streptomyces sp. 060524 and cytotoxicity of the products. World Journal of Microbiology and Biotechnology 25: 115-121 DOI: 10.1007/s11274-008-9872-6

51. Hwang SH, Tsai HJ, Liu JY, Morisseau C and Hammock BD*. (2007) Orally bioavailable potent soluble epoxide hydrolase inhibitors. Journal of Medicinal Chemistry 50: 3825-40 DOI: 10.1021/jm070270t

52. Jiao RH, Xu S, Liu JY, Ge HM, Ding H, Xu C, Zhu HL and Tan RX*. (2006) Chaetominine, a cytotoxic alkaloid produced by endophytic Chaetomium sp IFB-E015. Organic Letters 8: 5709-12 DOI: 10.1021/ol062257t

53. Liu JY, Huang LL, Ye YH, Zou WX, Guo ZJ and Tan RX*. (2006) Antifungal and new metabolites of Myrothecium sp. Z16, a fungus associated with white croaker Argyrosomus argentatus. Journal of Applied Microbiology 100: 195-202 DOI: 10.1111/j.1365-2672.2005.02760.x

54. Liu JY, Ye YH, Wang L, Shi DH and Tan RX*. (2005) New resveratrol oligomers from the stem bark of Hopea hainanensis. Helvetica Chimica Acta 88: 2910-7

55. Ye YH, Zhu HL, Song YC, Liu JY and Tan RX*. (2005) Structural revision of aspernigrin A, reisolated from Cladosporium herbarum IFB-E002. Journal of Natural Products 68: 1106-8 DOI: 10.1021/np050059p

56. Li Y, Song YC, Liu JY, Ma YM and Tan RX*. (2005) Anti-Helicobacter pylori substances from endophytic fungal cultures. World Journal of Microbiology and Biotechnology 21: 553-8 DOI: 10.1007/s11274-004-3273-2

57. Li Y, Xu C, Zhang Q, Liu JY and Tan RX*. (2005) In vitro anti-Helicobacter pylori action of 30 Chinese herbel medicines used to treat ulcer diseases. Journal of Ethnopharmacology 98: 329-33 DOI: 10.1016/j.jep.2005.01.020

58. Liu JY, Song YC, Zhang Z, Wang L, Guo ZJ, Zou WX and Tan RX*. (2004) Aspergillus fumigatus CY018, an endophytic fungus in Cynodon dactylon as a versatile producer of new and bioactive metabolites. Journal of Biotechnology 114: 279-87 DOI: 0.1016/j.jbiotec.2004.07.008

59. Ma YM, Li Y, Liu JY, Song YC, Tan RX*. (2004) Anti-Helicobacter pylori metabolites from Rhizoctonia sp. Cy064, an endophytic fungus in Cynodon dactylon. Fitoterapia 75, 451-6 DOI: 10.1016/j.fitote.2004.03.007

60. Zhao Y, Liu JY, Wang J, Wang L, Yin H, Tan RX and Xu Q*. (2004) Fumigaclavine C improves concanavalin A-induced liver injury in mice mainly via inhibiting TNF-α production and lymphocyte adhesion to extracellular matrices. Journal of Pharmacy and Pharmacology 56:775-82 DOI: 10.1211/0022357023592

61. Chen JH, Cui GY, Liu JY and Tan RX*. （2003） Pinelloside, a new antimicrobial cerebroside from Pinellia ternate. Phytochemistry 64: 903-6

62. Liu JY, Liu CH, Zou WX and Tan RX*. (2003) Leptosphaeric Acid, a metabolite with a novel skeleton from Leptosphaeria sp. IV403, an endophytic fungus in Artemisia annua. Helvetica Chimica Acta 86: 657-60

63. Zhou CX, Liu JY, Ye WC, Liu CH and Tan RX*. (2003) Neoverataline A and B, two antifungal alkaloids with a novel carbon skeleton from Veratrum taliense. Tetrahedron 59: 5743-7

64. Liu CH, Liu JY, Huang LL, Zou WX and Tan RX*. (2003) Absolute configuration of keisslone, a new antimicrobial metabolite from Keisslerriella sp. YS4108, a marine filamentous fungus. Planta Medica 69: 481-483

65. Cui GY, Liu JY and Tan RX*. (2003) A new antimicrobial flavonol glycoside from Alchornea davidii. Chinese Chemical Letters. 14:179-80

66. Liu JY, Liu CH, Zou WX, Tian X and Tan RX*. (2002) Leptosphaerone, a metabolite with a novel skeleton from Leptosphaeria sp. IV403, an endophytic fungus in Artemisia annua. Helvetica Chimica Acta 85：2664-